Advenchen Pharmaceuticals, LLC.

Quick facts

Phase 2 pipeline

• AL8326 high dose group · Immunology/Respiratory
  AL8326 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.
• AL8326 low dose group · Diabetes
  AL8326 is a small molecule that targets the SGLT2 receptor.
• AL8326 middle dose group · Diabetes
  AL8326 is a small molecule that targets the SGLT2 receptor.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Advenchen Pharmaceuticals, LLC. portfolio CI brief
• Advenchen Pharmaceuticals, LLC. pipeline updates RSS

Related

• Sector hub: All tracked pharma companies